Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
Past, present, and future of hormonal therapy in recurrent endometrial cancer.

International journal of women's health

Carlson MJ, Thiel KW, Leslie KK.
PMID: 24833920
Int J Womens Health. 2014 May 02;6:429-35. doi: 10.2147/IJWH.S40942. eCollection 2014.

Endometrial cancer is a heterogeneous disease. Type I cancers are hormonally driven, typically present with a low grade at an early stage, and are of endometrioid histology. These cancers are often cured by surgery, and the rate of recurrence...

Cite
Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health. 2014;6:429-35doi: 10.2147/IJWH.S40942.
Carlson, M. J., Thiel, K. W., & Leslie, K. K. (2014). Past, present, and future of hormonal therapy in recurrent endometrial cancer. International journal of women's health, 6429-35. https://doi.org/10.2147/IJWH.S40942
Carlson, Matthew J, et al. "Past, present, and future of hormonal therapy in recurrent endometrial cancer." International journal of women's health vol. 6 (2014): 429-35. doi: https://doi.org/10.2147/IJWH.S40942
Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health. 2014 May 02;6:429-35. doi: 10.2147/IJWH.S40942. eCollection 2014. PMID: 24833920; PMCID: PMC4014387.
Copy Download .nbib Format: NLM
miR-888: A Novel Cancer-Testis Antigen that Targets the Progesterone Receptor in Endometrial Cancer.

Translational oncology

Hovey AM, Devor EJ, Breheny PJ, Mott SL, Dai D, Thiel KW, Leslie KK.
PMID: 25926074
Transl Oncol. 2015 Apr;8(2):85-96. doi: 10.1016/j.tranon.2015.02.001.

Cancer-testis (CT) antigens are a large family of genes that are selectively expressed in human testis germ cells, overexpressed in a variety of tumors and predominantly located on the X chromosome. To date, all known CT antigens are protein-coding...

Cite
Hovey AM, Devor EJ, Breheny PJ, et al. miR-888: A Novel Cancer-Testis Antigen that Targets the Progesterone Receptor in Endometrial Cancer. Transl Oncol. 2015;8(2):85-96doi: 10.1016/j.tranon.2015.02.001.
Hovey, A. M., Devor, E. J., Breheny, P. J., Mott, S. L., Dai, D., Thiel, K. W., & Leslie, K. K. (2015). miR-888: A Novel Cancer-Testis Antigen that Targets the Progesterone Receptor in Endometrial Cancer. Translational oncology, 8(2), 85-96. https://doi.org/10.1016/j.tranon.2015.02.001
Hovey, Adriann M, et al. "miR-888: A Novel Cancer-Testis Antigen that Targets the Progesterone Receptor in Endometrial Cancer." Translational oncology vol. 8,2 (2015): 85-96. doi: https://doi.org/10.1016/j.tranon.2015.02.001
Hovey AM, Devor EJ, Breheny PJ, Mott SL, Dai D, Thiel KW, Leslie KK. miR-888: A Novel Cancer-Testis Antigen that Targets the Progesterone Receptor in Endometrial Cancer. Transl Oncol. 2015 Apr;8(2):85-96. doi: 10.1016/j.tranon.2015.02.001. PMID: 25926074; PMCID: PMC4415123.
Copy Download .nbib Format: NLM
Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53.

Obstetrics and gynecology international

Meng X, Dizon DS, Yang S, Wang X, Zhu D, Thiel KW, Leslie KK.
PMID: 24381593
Obstet Gynecol Int. 2013;2013:828165. doi: 10.1155/2013/828165. Epub 2013 Dec 07.

Serous uterine endometrial carcinomas are aggressive type II cancers with poor outcomes for which new treatment strategies are urgently needed, in particular, strategies that augment sensitivity to established chemotherapy regimens. The tumor suppressor gene TP53 is dysregulated in more...

Cite
Meng X, Dizon DS, Yang S, et al. Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53. Obstet Gynecol Int. 2013;2013:828165doi: 10.1155/2013/828165.
Meng, X., Dizon, D. S., Yang, S., Wang, X., Zhu, D., Thiel, K. W., & Leslie, K. K. (2013). Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53. Obstetrics and gynecology international, 2013828165. https://doi.org/10.1155/2013/828165
Meng, Xiangbing, et al. "Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53." Obstetrics and gynecology international vol. 2013 (2013): 828165. doi: https://doi.org/10.1155/2013/828165
Meng X, Dizon DS, Yang S, Wang X, Zhu D, Thiel KW, Leslie KK. Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53. Obstet Gynecol Int. 2013;2013:828165. doi: 10.1155/2013/828165. Epub 2013 Dec 07. PMID: 24381593; PMCID: PMC3871910.
Copy Download .nbib Format: NLM
microRNA expression patterns across seven cancers are highly correlated and dominated by evolutionarily ancient families.

Biomedical reports

Devor EJ, Schickling BM, Leslie KK.
PMID: 24748979
Biomed Rep. 2014 May;2(3):384-387. doi: 10.3892/br.2014.239. Epub 2014 Feb 17.

microRNAs (miRNAs) are involved in almost all normal and pathogenic eukaryotic cell processes. One area in which the influence of miRNAs is most prominent is cancer. Numerous expression surveys and more focused studies have revealed miRNA involvement in carcinogenesis,...

Cite
Devor EJ, Schickling BM, Leslie KK. microRNA expression patterns across seven cancers are highly correlated and dominated by evolutionarily ancient families. Biomed Rep. 2014;2(3):384-387doi: 10.3892/br.2014.239.
Devor, E. J., Schickling, B. M., & Leslie, K. K. (2014). microRNA expression patterns across seven cancers are highly correlated and dominated by evolutionarily ancient families. Biomedical reports, 2(3), 384-387. https://doi.org/10.3892/br.2014.239
Devor, Eric J, et al. "microRNA expression patterns across seven cancers are highly correlated and dominated by evolutionarily ancient families." Biomedical reports vol. 2,3 (2014): 384-387. doi: https://doi.org/10.3892/br.2014.239
Devor EJ, Schickling BM, Leslie KK. microRNA expression patterns across seven cancers are highly correlated and dominated by evolutionarily ancient families. Biomed Rep. 2014 May;2(3):384-387. doi: 10.3892/br.2014.239. Epub 2014 Feb 17. PMID: 24748979; PMCID: PMC3990207.
Copy Download .nbib Format: NLM
Placenta-specific protein 1: a potential key to many oncofetal-placental OB/GYN research questions.

Obstetrics and gynecology international

Devor EJ, Reyes HD, Santillan DA, Santillan MK, Onukwugha C, Goodheart MJ, Leslie KK.
PMID: 24757447
Obstet Gynecol Int. 2014;2014:678984. doi: 10.1155/2014/678984. Epub 2014 Mar 17.

Placenta-specific protein 1 (PLAC1) is a secreted protein found in trophoblasts. Several reports implicate a central role for PLAC1 in establishment and maintenance of the placenta. In addition to placentae PLAC1 is expressed in a variety of solids including...

Cite
Devor EJ, Reyes HD, Santillan DA, et al. Placenta-specific protein 1: a potential key to many oncofetal-placental OB/GYN research questions. Obstet Gynecol Int. 2014;2014:678984doi: 10.1155/2014/678984.
Devor, E. J., Reyes, H. D., Santillan, D. A., Santillan, M. K., Onukwugha, C., Goodheart, M. J., & Leslie, K. K. (2014). Placenta-specific protein 1: a potential key to many oncofetal-placental OB/GYN research questions. Obstetrics and gynecology international, 2014678984. https://doi.org/10.1155/2014/678984
Devor, Eric J, et al. "Placenta-specific protein 1: a potential key to many oncofetal-placental OB/GYN research questions." Obstetrics and gynecology international vol. 2014 (2014): 678984. doi: https://doi.org/10.1155/2014/678984
Devor EJ, Reyes HD, Santillan DA, Santillan MK, Onukwugha C, Goodheart MJ, Leslie KK. Placenta-specific protein 1: a potential key to many oncofetal-placental OB/GYN research questions. Obstet Gynecol Int. 2014;2014:678984. doi: 10.1155/2014/678984. Epub 2014 Mar 17. PMID: 24757447; PMCID: PMC3976915.
Copy Download .nbib Format: NLM
The miR-503 cluster is coordinately under-expressed in endometrial endometrioid adenocarcinoma and targets many oncogenes, cell cycle genes, DNA repair genes and chemotherapy response genes.

OncoTargets and therapy

Devor EJ, Cha E, Warrier A, Miller MD, Gonzalez-Bosquet J, Leslie KK.
PMID: 30425513
Onco Targets Ther. 2018 Oct 18;11:7205-7211. doi: 10.2147/OTT.S180921. eCollection 2018.

BACKGROUND: The miR-503 miRNA cluster, located at Xq23.1, is composed of six miRNAs; miR-424, miR-503, miR-542, miR-450a-1, miR-450a-2 and miR-450b. Numerous studies have focused on the relationship of one or two members of the cluster and various human cancers....

Cite
Devor EJ, Cha E, Warrier A, et al. The miR-503 cluster is coordinately under-expressed in endometrial endometrioid adenocarcinoma and targets many oncogenes, cell cycle genes, DNA repair genes and chemotherapy response genes. Onco Targets Ther. 2018;11:7205-7211doi: 10.2147/OTT.S180921.
Devor, E. J., Cha, E., Warrier, A., Miller, M. D., Gonzalez-Bosquet, J., & Leslie, K. K. (2018). The miR-503 cluster is coordinately under-expressed in endometrial endometrioid adenocarcinoma and targets many oncogenes, cell cycle genes, DNA repair genes and chemotherapy response genes. OncoTargets and therapy, 117205-7211. https://doi.org/10.2147/OTT.S180921
Devor, Eric J, et al. "The miR-503 cluster is coordinately under-expressed in endometrial endometrioid adenocarcinoma and targets many oncogenes, cell cycle genes, DNA repair genes and chemotherapy response genes." OncoTargets and therapy vol. 11 (2018): 7205-7211. doi: https://doi.org/10.2147/OTT.S180921
Devor EJ, Cha E, Warrier A, Miller MD, Gonzalez-Bosquet J, Leslie KK. The miR-503 cluster is coordinately under-expressed in endometrial endometrioid adenocarcinoma and targets many oncogenes, cell cycle genes, DNA repair genes and chemotherapy response genes. Onco Targets Ther. 2018 Oct 18;11:7205-7211. doi: 10.2147/OTT.S180921. eCollection 2018. PMID: 30425513; PMCID: PMC6203085.
Copy Download .nbib Format: NLM
Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma.

Experimental and therapeutic medicine

Devor EJ, DE Mik JN, Ramachandran S, Goodheart MJ, Leslie KK.
PMID: 22969950
Exp Ther Med. 2012 Apr;3(4):677-682. doi: 10.3892/etm.2012.458. Epub 2012 Jan 25.

Uterine carcinosarcoma (UCS) is a rare but very aggressive cancer of the female reproductive tract with an extremely poor prognosis. With the goal of understanding the role of microRNA (miRNA) dysregulation in these tumors, we profiled the expression of...

Cite
Devor EJ, DE Mik JN, Ramachandran S, et al. Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma. Exp Ther Med. 2012;3(4):677-682doi: 10.3892/etm.2012.458.
Devor, E. J., DE Mik, J. N., Ramachandran, S., Goodheart, M. J., & Leslie, K. K. (2012). Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma. Experimental and therapeutic medicine, 3(4), 677-682. https://doi.org/10.3892/etm.2012.458
Devor, Eric J, et al. "Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma." Experimental and therapeutic medicine vol. 3,4 (2012): 677-682. doi: https://doi.org/10.3892/etm.2012.458
Devor EJ, DE Mik JN, Ramachandran S, Goodheart MJ, Leslie KK. Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma. Exp Ther Med. 2012 Apr;3(4):677-682. doi: 10.3892/etm.2012.458. Epub 2012 Jan 25. PMID: 22969950; PMCID: PMC3438812.
Copy Download .nbib Format: NLM
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.

Clinical cancer research : an official journal of the American Association for Cancer Research

Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK.
PMID: 33766814
Clin Cancer Res. 2021 May 15;27(10):2734-2741. doi: 10.1158/1078-0432.CCR-20-4618. Epub 2021 Mar 25.

PURPOSE: This surgical window of opportunity (window) study assessed the short-term effect of medroxyprogesterone acetate (MPA) alone versus MPA plus the histone deacetylase (HDAC) inhibitor entinostat on regulation of progesterone receptor (PR) in women with newly diagnosed endometrioid endometrial...

Cite
Duska LR, Filiaci VL, Walker JL, et al. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021;27(10):2734-2741doi: 10.1158/1078-0432.CCR-20-4618.
Duska, L. R., Filiaci, V. L., Walker, J. L., Holman, L. L., Hill, E. K., Moore, R. G., Ring, K. L., Pearl, M. L., Muller, C. Y., Kushnir, C. L., Lankes, H. A., Samuelson, M. I., Carrick, K. S., Rajan, A., Rodgers, W. H., Kohn, E. C., Piekarz, R., & Leslie, K. K. (2021). A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2734-2741. https://doi.org/10.1158/1078-0432.CCR-20-4618
Duska, Linda R, et al. "A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2734-2741. doi: https://doi.org/10.1158/1078-0432.CCR-20-4618
Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 May 15;27(10):2734-2741. doi: 10.1158/1078-0432.CCR-20-4618. Epub 2021 Mar 25. PMID: 33766814; PMCID: PMC8127359.
Copy Download .nbib Format: NLM
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.

Clinical cancer research : an official journal of the American Association for Cancer Research

Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK.
PMID: 33766814
Clin Cancer Res. 2021 May 15;27(10):2734-2741. doi: 10.1158/1078-0432.CCR-20-4618. Epub 2021 Mar 25.

PURPOSE: This surgical window of opportunity (window) study assessed the short-term effect of medroxyprogesterone acetate (MPA) alone versus MPA plus the histone deacetylase (HDAC) inhibitor entinostat on regulation of progesterone receptor (PR) in women with newly diagnosed endometrioid endometrial...

Cite
Duska LR, Filiaci VL, Walker JL, et al. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021;27(10):2734-2741doi: 10.1158/1078-0432.CCR-20-4618.
Duska, L. R., Filiaci, V. L., Walker, J. L., Holman, L. L., Hill, E. K., Moore, R. G., Ring, K. L., Pearl, M. L., Muller, C. Y., Kushnir, C. L., Lankes, H. A., Samuelson, M. I., Carrick, K. S., Rajan, A., Rodgers, W. H., Kohn, E. C., Piekarz, R., & Leslie, K. K. (2021). A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2734-2741. https://doi.org/10.1158/1078-0432.CCR-20-4618
Duska, Linda R, et al. "A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2734-2741. doi: https://doi.org/10.1158/1078-0432.CCR-20-4618
Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 May 15;27(10):2734-2741. doi: 10.1158/1078-0432.CCR-20-4618. Epub 2021 Mar 25. PMID: 33766814; PMCID: PMC8127359.
Copy Download .nbib Format: NLM
The estrogen receptor joins other cancer biomarkers as a predictor of outcome.

Obstetrics and gynecology international

Leslie KK, Thiel KW, Reyes HD, Yang S, Zhang Y, Carlson MJ, Kumar NS, Dai DD.
PMID: 24223042
Obstet Gynecol Int. 2013;2013:479541. doi: 10.1155/2013/479541. Epub 2013 Oct 07.

Endometrial cancer, the most common gynecologic malignancy in the United States, is on the rise, and survival is worse today than 40 years ago. In order to improve the outcomes, better biomarkers that direct the choice of therapy are...

Cite
Leslie KK, Thiel KW, Reyes HD, et al. The estrogen receptor joins other cancer biomarkers as a predictor of outcome. Obstet Gynecol Int. 2013;2013:479541doi: 10.1155/2013/479541.
Leslie, K. K., Thiel, K. W., Reyes, H. D., Yang, S., Zhang, Y., Carlson, M. J., Kumar, N. S., & Dai, D. D. (2013). The estrogen receptor joins other cancer biomarkers as a predictor of outcome. Obstetrics and gynecology international, 2013479541. https://doi.org/10.1155/2013/479541
Leslie, Kimberly K, et al. "The estrogen receptor joins other cancer biomarkers as a predictor of outcome." Obstetrics and gynecology international vol. 2013 (2013): 479541. doi: https://doi.org/10.1155/2013/479541
Leslie KK, Thiel KW, Reyes HD, Yang S, Zhang Y, Carlson MJ, Kumar NS, Dai DD. The estrogen receptor joins other cancer biomarkers as a predictor of outcome. Obstet Gynecol Int. 2013;2013:479541. doi: 10.1155/2013/479541. Epub 2013 Oct 07. PMID: 24223042; PMCID: PMC3816067.
Copy Download .nbib Format: NLM
The oncoplacental gene placenta-specific protein 1 is highly expressed in endometrial tumors and cell lines.

Obstetrics and gynecology international

Devor EJ, Leslie KK.
PMID: 23935632
Obstet Gynecol Int. 2013;2013:807849. doi: 10.1155/2013/807849. Epub 2013 Jul 10.

Placenta-specific protein 1 (PLAC1) is a small secreted protein expressed exclusively in trophoblast cells in the mammalian placenta. PLAC1 is expressed early in gestation and is maintained throughout. It is thought to function in trophoblast invasion of the uterine...

Cite
Devor EJ, Leslie KK. The oncoplacental gene placenta-specific protein 1 is highly expressed in endometrial tumors and cell lines. Obstet Gynecol Int. 2013;2013:807849doi: 10.1155/2013/807849.
Devor, E. J., & Leslie, K. K. (2013). The oncoplacental gene placenta-specific protein 1 is highly expressed in endometrial tumors and cell lines. Obstetrics and gynecology international, 2013807849. https://doi.org/10.1155/2013/807849
Devor, Eric J, and Leslie, Kimberly K. "The oncoplacental gene placenta-specific protein 1 is highly expressed in endometrial tumors and cell lines." Obstetrics and gynecology international vol. 2013 (2013): 807849. doi: https://doi.org/10.1155/2013/807849
Devor EJ, Leslie KK. The oncoplacental gene placenta-specific protein 1 is highly expressed in endometrial tumors and cell lines. Obstet Gynecol Int. 2013;2013:807849. doi: 10.1155/2013/807849. Epub 2013 Jul 10. PMID: 23935632; PMCID: PMC3723095.
Copy Download .nbib Format: NLM
Blocking Epidermal Growth Factor Receptor Signaling in HTR-8/SVneo First Trimester Trophoblast Cells Results in Dephosphorylation of PKBα/AKT and Induces Apoptosis.

Obstetrics and gynecology international

Bolnick J, Albitar L, Laidler LL, Abdullah R, Leslie KK.
PMID: 21876698
Obstet Gynecol Int. 2011;2011:896896. doi: 10.1155/2011/896896. Epub 2011 Aug 21.

We identified a major peptide signaling target of EGF/EGFR pathway and explored the consequences of blocking or activating this pathway in the first trimester extravillous trophoblast cells, HTR-8/SVneo. A global analysis of protein phosphorylation was undertaken using novel technology...

Cite
Bolnick J, Albitar L, Laidler LL, et al. Blocking Epidermal Growth Factor Receptor Signaling in HTR-8/SVneo First Trimester Trophoblast Cells Results in Dephosphorylation of PKBα/AKT and Induces Apoptosis. Obstet Gynecol Int. 2011;2011:896896doi: 10.1155/2011/896896.
Bolnick, J., Albitar, L., Laidler, L. L., Abdullah, R., & Leslie, K. K. (2011). Blocking Epidermal Growth Factor Receptor Signaling in HTR-8/SVneo First Trimester Trophoblast Cells Results in Dephosphorylation of PKBα/AKT and Induces Apoptosis. Obstetrics and gynecology international, 2011896896. https://doi.org/10.1155/2011/896896
Bolnick, J, et al. "Blocking Epidermal Growth Factor Receptor Signaling in HTR-8/SVneo First Trimester Trophoblast Cells Results in Dephosphorylation of PKBα/AKT and Induces Apoptosis." Obstetrics and gynecology international vol. 2011 (2011): 896896. doi: https://doi.org/10.1155/2011/896896
Bolnick J, Albitar L, Laidler LL, Abdullah R, Leslie KK. Blocking Epidermal Growth Factor Receptor Signaling in HTR-8/SVneo First Trimester Trophoblast Cells Results in Dephosphorylation of PKBα/AKT and Induces Apoptosis. Obstet Gynecol Int. 2011;2011:896896. doi: 10.1155/2011/896896. Epub 2011 Aug 21. PMID: 21876698; PMCID: PMC3159379.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries